UCLA   

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

Patients are understandably concerned about the risks and benefits of radiation to an oozing, bleeding, and ulcerated breast.

If so, under what circumstances?

We usually recommend copper IUDs, but that's not feasible in all women.

Would you prefer TCHP over TCH? Would you consider adding an anthracycline?

Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...

Out of curiosity, I did tumor testing, and she does not have an activating ESR1 mutation.

Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...

Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...

Tamoxifen prophylaxis has not been studied in women <35 years old, but it would be reasonable to assume they would benefit.

Patient has hot flashes.

Or would you proceed with standard-of-care adjuvant approach for high risk patients?

Does the answer vary based on whether it is neo/adjuvant or metastatic setting?

Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?

Patient does not qualify for breast cancer screening by annual MRI per criteria (IBIS lifetime risk<20%, no known genetic predisposition,...

Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.

This is in regards to the risk of secondary cancers after radiation therapy or cytotoxic chemotherapy (such as anthracyclines) in an immunosuppre...

What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?

Would you use a regimen with lower incidence of neurotoxicity such as CMF or a taxane-based regimen with a low threshold to dose-reduce?

Some patients request chemotherapy scheduling adjustments to avoid feeling ill on major holidays. Delaying chemotherapy by a few days isn't of particu...

Example case: Patient given neoadjuvant docetaxel + cyclophophamide achieves a partial response after 3 cycles of Taxotere + cyclophosphamide but is u...

Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-men...

In the absence of data demonstrating a clinical benefit for one strategy versus the other, what do you do in practice?  

There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 200...

For example, would you order a PET/CT to evaluate for lymphatic or distant metastatic disease?

Does your institution do this routinely?

Is this in addition to or mutually exclusive from oncotype/mammaprint?